

Scott D Grosse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7697530/publications.pdf>

Version: 2024-02-01

248
papers

13,489
citations

20817

60
h-index

28297

105
g-index

257
all docs

257
docs citations

257
times ranked

15023
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity in Autism Spectrum Disorder Case-Finding Algorithms in United States Health Administrative Database Analyses. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4150-4163.	2.7	5
2	Economic evaluation of Zika Contraception Access Network in Puerto Rico during the 2016–17 Zika virus outbreak. <i>Contraception</i> , 2022, 107, 68-73.	1.5	2
3	Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection. <i>Current Medical Research and Opinion</i> , 2022, 38, 273-275.	1.9	6
4	Medicaid healthcare expenditures for infants with birth defects potentially related to Zika virus infection in North Carolina, 2011–2016. <i>Birth Defects Research</i> , 2022, 114, 80-89.	1.5	3
5	Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state. <i>Muscle and Nerve</i> , 2022, 65, 574-580.	2.2	1
6	Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines. <i>Applied Health Economics and Health Policy</i> , 2022, , 1.	2.1	1
7	Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019. <i>Journal of Pediatrics</i> , 2022, 246, 274-278.e2.	1.8	7
8	Post-traumatic stress disorder, anxiety, and depression among adults with congenital heart defects. <i>Birth Defects Research</i> , 2022, 114, 124-135.	1.5	6
9	Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 379-382.	1.3	4
10	Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003–2015. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 2950-2958.	2.7	17
11	Medical expenditures for hypertensive disorders during pregnancy that resulted in a live birth among privately insured women. <i>Pregnancy Hypertension</i> , 2021, 23, 155-162.	1.4	2
12	Health and economic outcomes of newborn screening for infantile-onset Pompe disease. <i>Genetics in Medicine</i> , 2021, 23, 758-766.	2.4	10
13	Spending on Young Children With Autism Spectrum Disorder in Employer-Sponsored Plans, 2011–2017. <i>Psychiatric Services</i> , 2021, 72, 16-22.	2.0	10
14	Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs. <i>Current Medical Research and Opinion</i> , 2021, 37, 769-779.	1.9	14
15	State-Level Health Care Expenditures Associated With Disability. <i>Public Health Reports</i> , 2021, 136, 441-450.	2.5	8
16	Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies. <i>Seminars in Perinatology</i> , 2021, 45, 151393.	2.5	26
17	Preterm birth lifetime costs in the United States in 2016: An update. <i>Seminars in Perinatology</i> , 2021, 45, 151390.	2.5	55
18	Monetary Valuation of Children’s Cognitive Outcomes in Economic Evaluations from a Societal Perspective: A Review. <i>Children</i> , 2021, 8, 352.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Cost or price of sequencing? Implications for economic evaluations in genomic medicine. <i>Genetics in Medicine</i> , 2021, 23, 1833-1835.	2.4	10
20	Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework. <i>Pediatrics</i> , 2021, 148, s45-s50.	2.1	1
21	Reading Proficiency Trends Following Newborn Hearing Screening Implementation. <i>Pediatrics</i> , 2021, 148, .	2.1	10
22	Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies. <i>Muscle and Nerve</i> , 2021, 64, 717-725.	2.2	3
23	Estimation of Coronavirus Disease 2019 Hospitalization Costs From a Large Electronic Administrative Discharge Database, March 2020â€“July 2021. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab561.	0.9	13
24	Exome sequencing: value is in the eye of the beholder. <i>Genetics in Medicine</i> , 2020, 22, 280-282.	2.4	5
25	National Health Care Expenditures Associated With Disability. <i>Medical Care</i> , 2020, 58, 826-832.	2.4	21
26	Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28703.	1.5	22
27	Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia. <i>International Journal of Neonatal Screening</i> , 2020, 6, 82.	3.2	11
28	Fragile X Syndrome-Associated Emergency Department Visits in the United States, 2006â€“2011. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2020, 125, 103-108.	1.6	0
29	Treatment Discontinuation within 3Â“Years of Levothyroxine Initiation among Children Diagnosed with Congenital Hypothyroidism. <i>Journal of Pediatrics</i> , 2020, 223, 136-140.	1.8	12
30	Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents With Congenital Adrenal Hyperplasia. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa152.	0.2	5
31	Infants with Congenital Disorders Identified Through Newborn Screening â€” United States, 2015â€“2017. <i>Morbidity and Mortality Weekly Report</i> , 2020, 69, 1265-1268.	15.1	37
32	Early Hearing Detection and Intervention in the United States: Achievements and Challenges in the 21 st Century. <i>China CDC Weekly</i> , 2020, 2, 378-382.	2.3	10
33	Private Insurance Reimbursements for Newborn Hearing Screening in the United States, 2013-2014 Birth Cohort. <i>Journal of Early Hearing Detection and Intervention</i> , 2020, 5, 13-19.	0.2	0
34	Is universal tumor testing for Lynch syndrome cost-effective? It depends!. <i>Genetics in Medicine</i> , 2019, 21, 252-253.	2.4	3
35	Genomic sequencing in acutely ill infants: what will it take to demonstrate clinical value?. <i>Genetics in Medicine</i> , 2019, 21, 269-271.	2.4	14
36	Avoiding Harm From Hyperbilirubinemia Screeningâ€”Reply. <i>JAMA Pediatrics</i> , 2019, 173, 1209.	6.2	0

#	ARTICLE	IF	CITATIONS
37	Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Affairs, 2019, 38, 328-328.	5.2	0
38	Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time. Pharmacoeconomics, 2019, 37, 461-473.	3.3	42
39	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet Journal of Rare Diseases, 2019, 14, 70.	2.7	9
40	Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. Haemophilia, 2019, 25, 456-462.	2.1	15
41	Assessing the Hereditary Hemorrhagic Telangiectasia Algorithms in a Community-Based Patient Population. , 2019, 23, .		4
42	Ensuring the Life-Span Benefits of Newborn Screening. Pediatrics, 2019, 144, e20190904.	2.1	13
43	Adherence to Recommended Care Guidelines in the Treatment of Preschool-Age Medicaid-Enrolled Children With a Diagnosis of ADHD. Psychiatric Services, 2019, 70, 26-34.	2.0	16
44	US State-Level Infertility Insurance Mandates and Health Plan Expenditures on Infertility Treatments. Maternal and Child Health Journal, 2019, 23, 623-632.	1.5	11
45	Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. Journal of Medical Economics, 2019, 22, 501-508.	2.1	37
46	Actions in Support of Newborn Screening for Critical Congenital Heart Disease – United States, 2011–2018. Morbidity and Mortality Weekly Report, 2019, 68, 107-111.	15.1	32
47	Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009–2015. Clinical Therapeutics, 2018, 40, 430-439.e1.	2.5	11
48	Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book. American Journal of Preventive Medicine, 2018, 54, 600-602.	3.0	38
49	Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States. Health Services Research, 2018, 53, 175-196.	2.0	330
50	Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genetics in Medicine, 2018, 20, 428-434.	2.4	42
51	Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genetics in Medicine, 2018, 20, 383-389.	2.4	49
52	Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths. Obstetrical and Gynecological Survey, 2018, 73, 260-262.	0.4	1
53	What Contribution Did Economic Evidence Make to the Adoption of Universal Newborn Hearing Screening Policies in the United States?. International Journal of Neonatal Screening, 2018, 4, 25.	3.2	14
54	Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010–2016. Pediatric Pulmonology, 2018, 53, 1611-1618.	2.0	33

#	ARTICLE	IF	CITATIONS
55	Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosisâ€‘Related Hospitalizations. Health Affairs, 2018, 37, 773-779.	5.2	27
56	Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. MDM Policy and Practice, 2018, 3, 238146831876381.	0.9	8
57	Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review. Applied Health Economics and Health Policy, 2018, 16, 765-778.	2.1	120
58	Progress in Documented Early Identification and Intervention for Deaf and Hard of Hearing Infants: CDC's Hearing Screening and Follow-up Survey, United States, 2006-2016. Journal of Early Hearing Detection and Intervention, 2018, 3, 1-7.	0.2	11
59	Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genetics in Medicine, 2017, 19, 121-126.	2.4	73
60	Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1. Genetics in Medicine, 2017, 19, 975-982.	2.4	27
61	Screening for Congenital Cytomegalovirus After Newborn Hearing Screening: What Comes Next?. Pediatrics, 2017, 139, e20163837.	2.1	16
62	Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection. Pediatrics, 2017, 139, .	2.1	129
63	Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 731-734.	1.3	18
64	Employer-Sponsored Plan Expenditures for Infants Born Preterm. Pediatrics, 2017, 140, .	2.1	41
65	Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths. JAMA - Journal of the American Medical Association, 2017, 318, 2111.	7.4	106
66	Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health. American Journal of Preventive Medicine, 2017, 53, S115-S117.	3.0	50
67	Are lower TSH cutoffs in neonatal screening for congenital hypothyroidism warranted?. European Journal of Endocrinology, 2017, 177, D1-D12.	3.7	81
68	The need for a next-generation public health response to rare diseases. Genetics in Medicine, 2017, 19, 489-490.	2.4	16
69	How Economic Findings Can Inform Prevention Research in Cardiovascular Disease. American Journal of Preventive Medicine, 2017, 53, S118-S120.	3.0	0
70	CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease. Morbidity and Mortality Weekly Report, 2017, 66, 888-890.	15.1	25
71	Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review. International Journal of Neonatal Screening, 2017, 3, 34.	3.2	17
72	Cost-effectiveness of Increasing Access to Contraception during the Zika Virus Outbreak, Puerto Rico, 2016. Emerging Infectious Diseases, 2017, 23, 74-82.	4.3	34

#	ARTICLE	IF	CITATIONS
73	Inpatient Hospitalization Costs Associated with Birth Defects Among Persons of All Ages â€” United States, 2013. Morbidity and Mortality Weekly Report, 2017, 66, 41-46.	15.1	95
74	In Reference to: â€œCost and Utility of Thrombophilia Testingâ€, Journal of Hospital Medicine, 2017, 12, 783-783.	1.4	4
75	<i>BRCA</i> Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18â€“64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas â€” United States, 2009â€“2014. MMWR Surveillance Summaries, 2017, 66, 1-11.	34.6	33
76	Spending by Californiaâ€™s Department of Developmental Services for Persons with Autism across Demographic and Expenditure Categories. PLoS ONE, 2016, 11, e0151970.	2.5	36
77	Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006â€“2010. PLoS ONE, 2016, 11, e0153257.	2.5	11
78	The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. Milbank Quarterly, 2016, 94, 366-391.	4.4	25
79	Observed and expected frequencies of structural hemoglobin variants in newborn screening surveys in Africa and the Middle East: deviations from Hardy-Weinberg equilibrium. Genetics in Medicine, 2016, 18, 265-274.	2.4	22
80	Cost-of-illness models for venous thromboembolism: One size does not fit all. Thrombosis Research, 2016, 145, 65-66.	1.7	1
81	Epidemiology matters: peering inside the â€œblack boxâ€ in economic evaluations of genetic testing. Genetics in Medicine, 2016, 18, 963-965.	2.4	0
82	Databases for Congenital Heart Defect Public Health Studies Across the Lifespan. Journal of the American Heart Association, 2016, 5, .	3.7	24
83	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet Journal of Rare Diseases, 2016, 11, 12.	2.7	38
84	Factors associated with the timeliness of postnatal surgical repair of spina bifida. Child's Nervous System, 2016, 32, 1479-1487.	1.1	16
85	Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. Maternal and Child Health Journal, 2016, 20, 693-700.	1.5	38
86	Retrospective Assessment of Cost Savings From Prevention. American Journal of Preventive Medicine, 2016, 50, S74-S80.	3.0	94
87	Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State. Journal of Pediatrics, 2016, 172, 127-135.	1.8	40
88	The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thrombosis Research, 2016, 137, 3-10.	1.7	345
89	Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2â€“5 Years â€” United States, 2008â€“2014. Morbidity and Mortality Weekly Report, 2016, 65, 443-450.	15.1	71
90	Factors associated with high hospital resource use in a populationâ€based study of children with orofacial clefts. Birth Defects Research Part A: Clinical and Molecular Teratology, 2015, 103, 127-143.	1.6	12

#	ARTICLE	IF	CITATIONS
91	What we don't know can hurt us: Nonresponse bias assessment in birth defects research. Birth Defects Research Part A: Clinical and Molecular Teratology, 2015, 103, 603-609.	1.6	2
92	Professional Fee Ratios for US Hospital Discharge Data. Medical Care, 2015, 53, 840-849.	2.4	68
93	Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012. Pediatric Blood and Cancer, 2015, 62, 2076-2081.	1.5	19
94	When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. Healthcare (Switzerland), 2015, 3, 860-878.	2.0	31
95	Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. Healthcare (Switzerland), 2015, 3, 1133-1157.	2.0	26
96	Universal State Newborn Screening Programs Can Reduce Health Disparities. JAMA Pediatrics, 2015, 169, 7.	6.2	30
97	A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola. Journal of Pediatrics, 2015, 167, 1314-1319.	1.8	41
98	Mortality of New York children with sickle cell disease identified through newborn screening. Genetics in Medicine, 2015, 17, 452-459.	2.4	26
99	Scoping review of patient- and family-oriented outcomes and measures for chronic pediatric disease. BMC Pediatrics, 2015, 15, 7.	1.7	20
100	Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 267-283.	1.4	13
101	The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. Genetics in Medicine, 2015, 17, 510-511.	2.4	30
102	Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010. Thrombosis Research, 2015, 135, 636-642.	1.7	26
103	Determinants of Venous Thromboembolism among Hospitalizations of US Adults: A Multilevel Analysis. PLoS ONE, 2015, 10, e0123842.	2.5	16
104	Understanding and Improving Health Education Among First-time Parents of Infants With Sickle Cell Anemia in Alabama. Journal of Pediatric Hematology/Oncology, 2015, 37, 35-42.	0.6	6
105	Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Tropical Medicine and International Health, 2015, 20, 184-187.	2.3	42
106	Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. Thrombosis Research, 2015, 135, 50-57.	1.7	91
107	Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. American Journal of Obstetrics and Gynecology, 2015, 212, 74.e1-74.e9.	1.3	99
108	Return on Investment and Economic Evaluation. , 2015, , 225-232.		1

#	ARTICLE	IF	CITATIONS
109	The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. <i>Genetics in Medicine</i> , 2014, 16, 33-39.	2.4	56
110	Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. <i>Genetics in Medicine</i> , 2014, 16, 225-227.	2.4	19
111	Does Newborn Screening Have 100% Sensitivity to Detect Salt-Wasting Congenital Adrenal Hyperplasia?. <i>JAMA Pediatrics</i> , 2014, 168, 970.	6.2	1
112	Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?. <i>European Journal of Human Genetics</i> , 2014, 22, 25-31.	2.8	23
113	Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. <i>International Journal of Infectious Diseases</i> , 2014, 22, 44-48.	3.3	176
114	A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability. <i>Research in Developmental Disabilities</i> , 2014, 35, 1518-1527.	2.2	56
115	A Public Health Economic Assessment of Hospitals' Cost to Screen Newborns for Critical Congenital Heart Disease. <i>Public Health Reports</i> , 2014, 129, 86-93.	2.5	37
116	Leveraging birth defects surveillance data for health services research. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 815-821.	1.6	6
117	Prevention of orofacial clefts caused by smoking: Implications of the Surgeon General's report. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 822-825.	1.6	16
118	Hospitalizations and associated costs in a population-based study of children with Down Syndrome born in Florida. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 826-836.	1.6	23
119	CDC Grand Rounds: preventing hospital-associated venous thromboembolism. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 190-3.	15.1	25
120	Laboratory testing and diagnostic coding for cytomegalovirus among privately insured infants in the United States: a retrospective study using administrative claims data. <i>BMC Pediatrics</i> , 2013, 13, 90.	1.7	10
121	Hospitalizations, costs, and mortality among infants with critical congenital heart disease: How important is timely detection?. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2013, 97, 664-672.	1.6	66
122	Racial/ethnic differences in hospital use and cost among a statewide population of children with Down syndrome. <i>Research in Developmental Disabilities</i> , 2013, 34, 3276-3287.	2.2	20
123	Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. <i>Genetics in Medicine</i> , 2013, 15, 222-228.	2.4	35
124	Modeling uncertain outcomes of genetic testing: factor V Leiden mutation and pregnant women. <i>Genetics in Medicine</i> , 2013, 15, 335-337.	2.4	1
125	Cost-Effectiveness of Routine Screening for Critical Congenital Heart Disease in US Newborns. <i>Pediatrics</i> , 2013, 132, e595-e603.	2.1	91
126	U.S. Trends in Computed Tomography Use and Diagnoses in Emergency Department Visits by Patients With Symptoms Suggestive of Pulmonary Embolism, 2001-2009. <i>Academic Emergency Medicine</i> , 2013, 20, 1033-1040.	1.8	59

#	ARTICLE	IF	CITATIONS
127	Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia. <i>Pediatrics</i> , 2013, 132, 677-683.	2.1	77
128	Factors Associated With Late Detection of Critical Congenital Heart Disease in Newborns. <i>Pediatrics</i> , 2013, 132, e604-e611.	2.1	44
129	Trends in In-Hospital Deaths Among Hospitalizations With Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2012, 172, 960-1.	3.8	48
130	Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. <i>Genetics in Medicine</i> , 2012, 14, 703-712.	2.4	34
131	A National Profile of Health Care and Family Impacts of Children With Muscular Dystrophy and Special Health Care Needs in the United States. <i>Journal of Child Neurology</i> , 2012, 27, 569-576.	1.4	16
132	Trends in Venous Thromboembolism-Related Hospitalizations, 1994â€“2009. <i>Pediatrics</i> , 2012, 130, e812-e820.	2.1	61
133	Decision Analysis, Economic Evaluation, and Newborn Screening. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 758-760.	0.4	1
134	Autism Spectrum Disorders and Health Care Expenditures. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2012, 33, 2-8.	1.1	116
135	Hospital use, associated costs, and payer status for infants born with spina bifida. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2012, 94, 1044-1053.	1.6	24
136	Health Utility Elicitation. <i>Pharmacoeconomics</i> , 2012, 30, 83-86.	3.3	20
137	Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children. <i>Research in Developmental Disabilities</i> , 2012, 33, 832-840.	2.2	83
138	Health care expenditures associated with venous thromboembolism among children. <i>Thrombosis Research</i> , 2012, 129, 583-587.	1.7	24
139	The Jamaican Historical Experience of the Impact of Educational Interventions on Sickle Cell Disease Child Mortality. <i>American Journal of Preventive Medicine</i> , 2012, 42, e101-e103.	3.0	10
140	Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002â€“2008. <i>Contraception</i> , 2012, 85, 155-159.	1.5	19
141	Laboratory testing for cytomegalovirus among pregnant women in the United States: a retrospective study using administrative claims data. <i>BMC Infectious Diseases</i> , 2012, 12, 334.	2.9	5
142	Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al.. <i>Thrombosis and Haemostasis</i> , 2012, 107, 192-193.	3.4	23
143	Prevention of Venous Thromboembolism in Pregnancy: A Review of Guidelines, 2000â€“2011. <i>Journal of Women's Health</i> , 2012, 21, 611-615.	3.3	25
144	Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 268-275.	2.1	69

#	ARTICLE	IF	CITATIONS
145	Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 276-283.	2.1	63
146	Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001-2008 National Hospital Discharge Survey. <i>PLoS ONE</i> , 2012, 7, e34048.	2.5	14
147	Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening. <i>Ethnicity and Health</i> , 2011, 16, 377-388.	2.5	13
148	Disability Among Individuals with Sickle Cell Disease. <i>American Journal of Preventive Medicine</i> , 2011, 41, S390-S397.	3.0	35
149	A Public Health Framework for Rare Blood Disorders. <i>American Journal of Preventive Medicine</i> , 2011, 41, S319-S323.	3.0	13
150	Sickle Cell Disease in Africa. <i>American Journal of Preventive Medicine</i> , 2011, 41, S398-S405.	3.0	470
151	Characteristics of users of intrauterine devices and other reversible contraceptive methods in the United States. <i>Fertility and Sterility</i> , 2011, 96, 1138-1144.	1.0	25
152	Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level?. <i>Archives of Disease in Childhood</i> , 2011, 96, 374-379.	1.9	169
153	Medical expenditures of children in the United States with fetal alcohol syndrome. <i>Neurotoxicology and Teratology</i> , 2011, 33, 322-324.	2.4	31
154	The role of health technology assessment in coverage decisions on newborn screening. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 313-321.	0.5	18
155	Measuring health and well-being effects in family caregivers of children with craniofacial malformations. <i>Quality of Life Research</i> , 2011, 20, 1487-1495.	3.1	34
156	Variation in immunoreactive trypsinogen concentrations among michigan newborns and implications for cystic fibrosis newborn screening. <i>Pediatric Pulmonology</i> , 2011, 46, 125-130.	2.0	21
157	Health care expenditures among children with and those without spina bifida enrolled in Medicaid in North Carolina. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2011, 91, 1019-1027.	1.6	14
158	Strategies for Implementing Screening for Critical Congenital Heart Disease. <i>Pediatrics</i> , 2011, 128, e1259-e1267.	2.1	344
159	The Continuing Health Burden of Congenital Hypothyroidism in the Era of Neonatal Screening. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1671-1673.	3.6	10
160	Attitudes Toward Newborn Screening for Cytomegalovirus Infection. <i>Pediatrics</i> , 2011, 128, e1434-e1442.	2.1	27
161	The Economic Costs of Autism: A Review. , 2011, , 1347-1360.		50
162	The Income-Based Human Capital Valuation Methods in Public Health Economics Used by Forensic Economics. <i>Journal of Forensic Economics</i> , 2011, 22, 43-57.	0.3	10

#	ARTICLE	IF	CITATIONS
163	Outpatient medical conditions among children and adults with spina bifida in the United States: Frequency and expenditures. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2010, 3, 177-185.	0.5	8
164	Prevalence of Venous Thromboembolism Among Privately Insured US Adults. <i>Archives of Internal Medicine</i> , 2010, 170, 1774.	3.8	9
165	Attention-Deficit/Hyperactivity Disorder, Conduct Disorder, and Young Adult Intimate Partner Violence. <i>Archives of General Psychiatry</i> , 2010, 67, 1179.	12.3	58
166	Points to consider in assessing and appraising predictive genetic tests. <i>Journal of Community Genetics</i> , 2010, 1, 185-194.	1.2	22
167	Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 249-254.	3.6	31
168	Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. <i>BMC Pediatrics</i> , 2010, 10, 9.	1.7	67
169	What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to say. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 209-211.	1.3	3
170	Employment impact and financial burden for families of children with fragile X syndrome: findings from the National Fragile X Survey. <i>Journal of Intellectual Disability Research</i> , 2010, 54, 918-928.	2.0	38
171	Late-treated Phenylketonuria and Partial Reversibility of Intellectual Impairment. <i>Child Development</i> , 2010, 81, 200-211.	3.0	29
172	The Impact of Transient Hypothyroidism on the Increasing Rate of Congenital Hypothyroidism in the United States. <i>Pediatrics</i> , 2010, 125, S54-S63.	2.1	85
173	Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics. <i>Public Health Genomics</i> , 2010, 13, 106-115.	1.0	114
174	QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 293-308.	1.4	31
175	Sociodemographic Characteristics of Families of Children with Down Syndrome and the Economic Impacts of Child Disability on Families. <i>International Review of Research in Mental Retardation</i> , 2010, , 257-294.	0.7	16
176	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. <i>Genetics in Medicine</i> , 2010, 12, 93-104.	2.4	250
177	Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. <i>Medical Decision Making</i> , 2010, 30, 328-340.	2.4	99
178	Administrative Data Sets and Health Services Research on Hemoglobinopathies. <i>American Journal of Preventive Medicine</i> , 2010, 38, S557-S567.	3.0	50
179	Emergency Department Visits Made by Patients with Sickle Cell Disease. <i>American Journal of Preventive Medicine</i> , 2010, 38, S536-S541.	3.0	166
180	Sickle Cell Disease-Related Pediatric Medical Expenditures in the U.S.. <i>American Journal of Preventive Medicine</i> , 2010, 38, S550-S556.	3.0	74

#	ARTICLE	IF	CITATIONS
181	Prevalence of Congenital Hypothyroidism—Current Trends and Future Directions: Workshop Summary. <i>Pediatrics</i> , 2010, 125, S31-S36.	2.1	67
182	Evaluation of the Validity and Utility of Genetic Testing for Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2010, 686, 115-131.	1.6	50
183	Labor Market Productivity Costs for Caregivers of Children with Spina Bifida: A Population-Based Analysis. <i>Medical Decision Making</i> , 2009, 29, 23-32.	2.4	31
184	Personal utility and genomic information: Look before you leap. <i>Genetics in Medicine</i> , 2009, 11, 575-576.	2.4	73
185	Models of Comprehensive Multidisciplinary Care for Individuals in the United States With Genetic Disorders. <i>Pediatrics</i> , 2009, 123, 407-412.	2.1	147
186	Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease: A Scientific Statement from the AHA and AAP. <i>Pediatrics</i> , 2009, 124, 823-836.	2.1	275
187	Trends in Pediatric Sickle Cell Disease-Related Mortality in the United States, 1983-2002. <i>Journal of Pediatrics</i> , 2009, 154, 541-545.	1.8	133
188	Hospital use and associated costs of children aged zero to two years with craniofacial malformations in Massachusetts. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2009, 85, 925-934.	1.6	35
189	Impact of Spina Bifida on Parental Caregivers: Findings from a Survey of Arkansas Families. <i>Journal of Child and Family Studies</i> , 2009, 18, 574-581.	1.3	35
190	Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. <i>Pediatric Blood and Cancer</i> , 2009, 53, 642-646.	1.5	96
191	Healthcare expenditures for privately insured people with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2009, 44, 989-996.	2.0	63
192	Challenges of translating genetic tests into clinical and public health practice. <i>Nature Reviews Genetics</i> , 2009, 10, 489-495.	16.3	101
193	Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease. <i>Circulation</i> , 2009, 120, 447-458.	1.6	220
194	Newborn screening for congenital cytomegalovirus: Options for hospital-based and public health programs. <i>Journal of Clinical Virology</i> , 2009, 46, S32-S36.	3.1	46
195	Hospitalization for urinary tract infections and the quality of preventive health care received by people with spina bifida. <i>Disability and Health Journal</i> , 2009, 2, 145-152.	2.8	35
196	Economic Productivity by Age and Sex. <i>Medical Care</i> , 2009, 47, S94-S103.	2.4	108
197	Utilization of a Medicaid-Funded Intervention for Children With Autism. <i>Psychiatric Services</i> , 2009, 60, 549-552.	2.0	35
198	Disability and Disability-Adjusted Life Years: Not the Same. <i>Public Health Reports</i> , 2009, 124, 197-202.	2.5	66

#	ARTICLE	IF	CITATIONS
199	Children with Orofacial Clefts: Health-Care Use and Costs among a Privately Insured Population. Public Health Reports, 2009, 124, 447-453.	2.5	124
200	Assessing the evidence for clinical utility in newborn screening. , 2009, , 517-532.		4
201	Economic evaluations of newborn screening. , 2009, , 113-132.		6
202	The economic impact of an urban asthma management program. American Journal of Managed Care, 2009, 15, 345-51.	1.1	19
203	Health state preference scores for children with permanent childhood hearing loss: a comparative analysis of the QWB and HUI3. Quality of Life Research, 2008, 17, 943-953.	3.1	27
204	Medical Expenditures for Children with an Autism Spectrum Disorder in a Privately Insured Population. Journal of Autism and Developmental Disorders, 2008, 38, 546-552.	2.7	128
205	Health Care Expenditures for Infants and Young Children with Down Syndrome in a Privately Insured Population. Journal of Pediatrics, 2008, 153, 241-246.	1.8	71
206	Attention-Deficit/Hyperactivity Disorder Symptoms and Child Maltreatment: A Population-Based Study. Journal of Pediatrics, 2008, 153, 851-856.	1.8	166
207	Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genetics in Medicine, 2008, 10, 648-654.	2.4	112
208	Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: A quantitative assessment. Journal of Clinical Virology, 2008, 41, 57-62.	3.1	301
209	Economic Evaluation of a Neural Tube Defect Recurrenceâ€“Prevention Program. American Journal of Preventive Medicine, 2008, 35, 572-577.	3.0	51
210	Long-term economic effect of early childhood nutrition. Lancet, The, 2008, 371, 365-366.	13.7	14
211	Health Care Utilization and Expenditures for Children and Young Adults With Muscular Dystrophy in a Privately Insured Population. Journal of Child Neurology, 2008, 23, 883-888.	1.4	43
212	Measures of Follow-Up in Early Hearing Detection and Intervention Programs: A Need for Standardization. American Journal of Audiology, 2008, 17, 60-67.	1.2	25
213	Assessing cost-effectiveness in healthcare: history of the \$50,000 per QALY threshold. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 165-178.	1.4	543
214	Lessons from Cost-Effectiveness Research for United States Public Health Policy. Annual Review of Public Health, 2007, 28, 365-391.	17.4	105
215	How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?. Hormone Research in Paediatrics, 2007, 67, 284-291.	1.8	63
216	Outcomes in CAH: Need for Evidence-Based Estimates. Hormone Research in Paediatrics, 2007, 68, 203-203.	1.8	2

#	ARTICLE	IF	CITATIONS
217	Cost-effectiveness of a folic acid fortification program in Chile. <i>Health Policy</i> , 2007, 83, 295-303.	3.0	57
218	Newborn screening for inherited metabolic disease. <i>Lancet, The</i> , 2007, 369, 5-6.	13.7	15
219	Determining the Effect of Newborn Hearing Screening Legislation: An Analysis of State Hearing Screening Rates. <i>Public Health Reports</i> , 2007, 122, 198-205.	2.5	32
220	Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2007, 79, 552-558.	1.6	145
221	Folic acid supplementation and neural tube defect recurrence prevention. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2007, 79, 737-742.	1.6	55
222	Issues related to the diagnosis and treatment of autism spectrum disorders. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2007, 13, 129-135.	3.6	87
223	New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. <i>Reviews in Medical Virology</i> , 2007, 17, 355-363.	8.3	969
224	Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. <i>Journal of Pediatrics</i> , 2006, 149, 362-366.	1.8	98
225	Self-selection and evaluation of influenza vaccination effectiveness among elderly. <i>Vaccine</i> , 2006, 24, 6374-6375.	3.8	4
226	Quantifying the health benefits of genetic tests: The importance of a population perspective. <i>Genetics in Medicine</i> , 2006, 8, 191-195.	2.4	29
227	What is the clinical utility of genetic testing?. <i>Genetics in Medicine</i> , 2006, 8, 448-450.	2.4	244
228	The Business Case for Preconception Care: Methods and Issues. <i>Maternal and Child Health Journal</i> , 2006, 10, 93-99.	1.5	25
229	From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels. <i>Pediatrics</i> , 2006, 117, 923-929.	2.1	112
230	The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. <i>Genetics in Medicine</i> , 2006, 8, 205-212.	2.4	125
231	Cost Savings From Universal Newborn Hearing Screening. <i>Pediatrics</i> , 2006, 118, 844a-845.	2.1	6
232	Reevaluating the Benefits of Folic Acid Fortification in the United States: Economic Analysis, Regulation, and Public Health. <i>American Journal of Public Health</i> , 2005, 95, 1917-1922.	2.7	91
233	Health state preference scores of children with spina bifida and their caregivers. <i>Quality of Life Research</i> , 2005, 14, 1087-1098.	3.1	57
234	The Cost Effectiveness of Universal versus Selective Newborn Screening for Sickle Cell Disease in the US and the UK. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 239-247.	2.1	36

#	ARTICLE	IF	CITATIONS
235	Does newborn screening save money? The difference between cost-effective and cost-saving interventions. <i>Journal of Pediatrics</i> , 2005, 146, 168-170.	1.8	33
236	Exploring options for expanded newborn screening. <i>Journal of Law, Medicine and Ethics</i> , 2005, 33, 46-8.	0.9	4
237	The Skinny on COI Analysis. <i>Obesity</i> , 2004, 12, 1189-1189.	4.0	4
238	Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. <i>MMWR Recommendations and Reports</i> , 2004, 53, 1-29.	61.1	43
239	Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. <i>MMWR Recommendations and Reports</i> , 2004, 53, 1-36.	61.1	73
240	Quality monitoring for early hearing detection and intervention programs to optimize performance. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2003, 9, 73-78.	3.6	15
241	Second-hand Smoke Exposure and Blood Lead Levels in U.S. Children. <i>Epidemiology</i> , 2003, 14, 719-727.	2.7	80
242	Economic gains resulting from the reduction in children's exposure to lead in the United States.. <i>Environmental Health Perspectives</i> , 2002, 110, 563-569.	6.0	266
243	Assisting states in assessing newborn screening options. <i>Public Health Reports</i> , 2001, 116, 169-172.	2.5	3
244	Genetics and prevention effectiveness. , 2000, , 329-360.		0
245	â€œRegime Type and Performance: A Blind Alley?â€ <i>Comparative Political Studies</i> , 1982, 14, 543-548.	3.6	3
246	On the Alleged Antebellum Surge in Wage Differentials: A Critique of Williamson and Lindert. <i>Journal of Economic History</i> , 1982, 42, 413-418.	1.2	6
247	The politics of family planning in the Maghrib. <i>Studies in Comparative International Development</i> , 1982, 17, 22-48.	1.7	2
248	ECONOMIC COSTS OF MENTAL RETARDATION, CEREBRAL PALSY, HEARING LOSS, AND VISION IMPAIRMENT. <i>Research in Social Science and Disability</i> , 0, , 207-228.	0.1	46